The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Some online pharmacies sell semaglutide and tirzepatide that are ineffective, unsafe, or an outright scam. Here’s how to find ...

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.